JP2014528403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528403A5 JP2014528403A5 JP2014532481A JP2014532481A JP2014528403A5 JP 2014528403 A5 JP2014528403 A5 JP 2014528403A5 JP 2014532481 A JP2014532481 A JP 2014532481A JP 2014532481 A JP2014532481 A JP 2014532481A JP 2014528403 A5 JP2014528403 A5 JP 2014528403A5
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- pyrazol
- urea
- tert
- naphthalen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000006673 Asthma Diseases 0.000 claims 10
- -1 3- (tert-butyl) -1- (p-tolyl) -1H-pyrazol-5-yl Chemical group 0.000 claims 9
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 206010006451 Bronchitis Diseases 0.000 claims 5
- 206010006458 Bronchitis chronic Diseases 0.000 claims 5
- 208000007451 Chronic Bronchitis Diseases 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 5
- 206010014561 Emphysema Diseases 0.000 claims 5
- 201000003883 cystic fibrosis Diseases 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 201000000306 sarcoidosis Diseases 0.000 claims 5
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 4
- 208000002205 Allergic Conjunctivitis Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 206010010741 Conjunctivitis Diseases 0.000 claims 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 4
- 208000010247 Contact Dermatitis Diseases 0.000 claims 4
- 206010012434 Dermatitis allergic Diseases 0.000 claims 4
- 206010012442 Dermatitis contact Diseases 0.000 claims 4
- 206010017758 Gastric cancer Diseases 0.000 claims 4
- 206010025650 Malignant melanoma Diseases 0.000 claims 4
- 206010027476 Metastasis Diseases 0.000 claims 4
- 206010033645 Pancreatitis Diseases 0.000 claims 4
- 206010039083 Rhinitis Diseases 0.000 claims 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000010105 allergic rhinitis Diseases 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 239000004202 carbamide Substances 0.000 claims 4
- 201000011231 colorectal cancer Diseases 0.000 claims 4
- 231100000080 dermatitis contact Toxicity 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 201000004681 psoriasis Diseases 0.000 claims 4
- 201000009890 sinusitis Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 201000006704 ulcerative colitis Diseases 0.000 claims 4
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 3
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 3
- 230000001684 chronic Effects 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 210000001503 Joints Anatomy 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010047461 Viral infection Diseases 0.000 claims 2
- 208000001756 Virus Disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 201000006233 congestive heart failure Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 210000000056 organs Anatomy 0.000 claims 2
- 230000000241 respiratory Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 230000017613 viral reproduction Effects 0.000 claims 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N (2R,3R,4S)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- UBHCCGHQPDLGDY-UHFFFAOYSA-N 1-[4-(2-anilinopyrimidin-4-yl)oxynaphthalen-1-yl]-3-[5-tert-butyl-2-(4-hydroxyphenyl)pyrazol-3-yl]urea Chemical compound C=1C=C(O)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC(N=1)=CC=NC=1NC1=CC=CC=C1 UBHCCGHQPDLGDY-UHFFFAOYSA-N 0.000 claims 1
- WMEVWPPRBPPTRV-UHFFFAOYSA-N 1-[4-(2-anilinopyrimidin-4-yl)oxynaphthalen-1-yl]-3-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=CC=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 WMEVWPPRBPPTRV-UHFFFAOYSA-N 0.000 claims 1
- DBXJNQABFNNKPN-UHFFFAOYSA-N 1-[4-(2-anilinopyrimidin-4-yl)oxynaphthalen-1-yl]-3-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=CC=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 DBXJNQABFNNKPN-UHFFFAOYSA-N 0.000 claims 1
- YEMXWTXOSTZPEB-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[4-[2-(4-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=CC(O)=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 YEMXWTXOSTZPEB-UHFFFAOYSA-N 0.000 claims 1
- NSYKHTWNGWUTST-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2,4-dihydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC(O)=CC=4)O)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 NSYKHTWNGWUTST-UHFFFAOYSA-N 0.000 claims 1
- PHWDSIFWTAWWTO-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2,4-dimethoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound COC1=CC(OC)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 PHWDSIFWTAWWTO-UHFFFAOYSA-N 0.000 claims 1
- ONVRBAWIVFIJHQ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2,5-dimethylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC=C(C)C=4)C)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 ONVRBAWIVFIJHQ-UHFFFAOYSA-N 0.000 claims 1
- FTOGPTPILJXAPZ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-chloro-4-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC(O)=CC=4)Cl)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 FTOGPTPILJXAPZ-UHFFFAOYSA-N 0.000 claims 1
- KPHLJVDHJFLLFQ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-fluoro-4-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC(O)=CC=4)F)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 KPHLJVDHJFLLFQ-UHFFFAOYSA-N 0.000 claims 1
- YSCGLTBNMHIWFZ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-fluoroanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC=CC=4)F)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 YSCGLTBNMHIWFZ-UHFFFAOYSA-N 0.000 claims 1
- OKZIGNXMBPUUKU-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound COC1=CC=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 OKZIGNXMBPUUKU-UHFFFAOYSA-N 0.000 claims 1
- IHAAICCNNPXTHZ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC=CC=4)C)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 IHAAICCNNPXTHZ-UHFFFAOYSA-N 0.000 claims 1
- AUNDYKNGIPQOPL-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-propan-2-ylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound CC(C)C1=CC=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 AUNDYKNGIPQOPL-UHFFFAOYSA-N 0.000 claims 1
- KNRZDHNOISHOGX-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3,4-dimethoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 KNRZDHNOISHOGX-UHFFFAOYSA-N 0.000 claims 1
- VOHADHHZHANGKB-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-chloro-4-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=C(Cl)C(OC)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 VOHADHHZHANGKB-UHFFFAOYSA-N 0.000 claims 1
- PDEVFPKHVTXCFJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-fluoro-4-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(F)C(O)=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 PDEVFPKHVTXCFJ-UHFFFAOYSA-N 0.000 claims 1
- QJGQXNFWEATZQP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-fluoroanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(F)C=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 QJGQXNFWEATZQP-UHFFFAOYSA-N 0.000 claims 1
- HICTUWNTIGIPDG-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-hydroxy-4-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(O)C(C)=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 HICTUWNTIGIPDG-UHFFFAOYSA-N 0.000 claims 1
- HFJAHIJCNYORLF-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(O)C=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 HFJAHIJCNYORLF-UHFFFAOYSA-N 0.000 claims 1
- DQXDDNKSKQUYFA-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound COC1=CC=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 DQXDDNKSKQUYFA-UHFFFAOYSA-N 0.000 claims 1
- CKGGLZNZJRZRTM-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(3-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C)C=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 CKGGLZNZJRZRTM-UHFFFAOYSA-N 0.000 claims 1
- HAKVAEKWYIEPSR-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-chloro-2-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC(Cl)=CC=4)C)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 HAKVAEKWYIEPSR-UHFFFAOYSA-N 0.000 claims 1
- CTDYPDKXAYTBGR-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-ethoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(OCC)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 CTDYPDKXAYTBGR-UHFFFAOYSA-N 0.000 claims 1
- VBXDFGPLWMFEQW-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-fluoroanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=CC(F)=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 VBXDFGPLWMFEQW-UHFFFAOYSA-N 0.000 claims 1
- JLWQAVMMXAMIFK-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-hydroxy-2-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC(O)=CC=4)C)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 JLWQAVMMXAMIFK-UHFFFAOYSA-N 0.000 claims 1
- VPQXOTKFLVTQBB-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-hydroxy-3-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=C(O)C(OC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 VPQXOTKFLVTQBB-UHFFFAOYSA-N 0.000 claims 1
- VFDXVDLISMVQFY-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-hydroxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=CC(O)=CC=4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 VFDXVDLISMVQFY-UHFFFAOYSA-N 0.000 claims 1
- AIRVOCDKJXGJQV-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(OC)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 AIRVOCDKJXGJQV-UHFFFAOYSA-N 0.000 claims 1
- CXRISVPNMXQWAR-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(4-methylanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 CXRISVPNMXQWAR-UHFFFAOYSA-N 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 206010061768 Chronic respiratory disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229960003752 Oseltamivir Drugs 0.000 claims 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N Oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 1
- 229960002194 Oseltamivir phosphate Drugs 0.000 claims 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 1
- 229960001028 Zanamivir Drugs 0.000 claims 1
- 230000000840 anti-viral Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11183688.8A EP2578582A1 (en) | 2011-10-03 | 2011-10-03 | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
EP11183688.8 | 2011-10-03 | ||
PCT/GB2012/052444 WO2013050756A1 (en) | 2011-10-03 | 2012-10-03 | L-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p3i map kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014528403A JP2014528403A (ja) | 2014-10-27 |
JP2014528403A5 true JP2014528403A5 (US07846941-20101207-C00217.png) | 2015-10-08 |
JP6023204B2 JP6023204B2 (ja) | 2016-11-09 |
Family
ID=47018246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014532481A Active JP6023204B2 (ja) | 2011-10-03 | 2012-10-03 | p3iMAPキナーゼ阻害剤としてのl−ピラゾリル−3−(4−((2−アニリノピリミジン−4−イル)オキシ)ナフタレン−1−イル)尿素 |
Country Status (4)
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5511680B2 (ja) | 2007-12-19 | 2014-06-04 | キャンサー・リサーチ・テクノロジー・リミテッド | ピリド[2,3−b]ピラジン−8−置換化合物及びその使用 |
CN104945401B (zh) | 2010-02-01 | 2017-09-05 | 癌症研究技术有限公司 | Ip化合物及它们在治疗中的应用 |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
AU2012320300C1 (en) | 2011-10-03 | 2017-06-01 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP kinase inhibitors |
GB201214750D0 (en) * | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
EP2981526B1 (en) | 2013-04-02 | 2021-11-03 | Oxular Acquisitions Limited | Intermediates useful in the preparation of naphthylurea derivatives useful as kinase inhibitors |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
EP3083604A1 (en) | 2013-12-20 | 2016-10-26 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
MX371353B (es) | 2014-02-14 | 2020-01-27 | Respivert Ltd | Compuestos heterociclicos aromaticos como compuestos antiinflamatorios. |
MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
EA201892213A1 (ru) | 2016-04-06 | 2019-05-31 | Топайверт Фарма Лимитед | Ингибиторы киназ |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2239806T3 (es) | 1997-06-19 | 2005-10-01 | Bristol-Myers Squibb Pharma Company | Inhibidores del factor xa con un grupo de especificidad neutro p1. |
US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
JP2001526222A (ja) | 1997-12-22 | 2001-12-18 | バイエル コーポレイション | アリールおよびヘテロアリール置換複素環尿素を使用するp38キナーゼ活性の阻害 |
UA67763C2 (uk) | 1997-12-22 | 2004-07-15 | Байер Фармасьютікалс Корпорейшн | Арил- та гетероарилзаміщені гетероциклічні похідні сечовини, фармацевтична композиція та спосіб лікування захворювання, спричиненого кіназою raf |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
ATE312823T1 (de) | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
MXPA02004594A (es) | 1999-11-16 | 2002-10-23 | Boehringer Ingelheim Pharma | Derivados de urea como agentes anti-inflamatorios. |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
EP1259485B1 (en) | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
WO2002083628A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused compounds |
CA2445003A1 (en) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
ES2284887T3 (es) | 2001-07-11 | 2007-11-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Metodos para tratar enfermedades transmitidas por citocinas. |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
ATE386030T1 (de) * | 2002-02-25 | 2008-03-15 | Boehringer Ingelheim Pharma | 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen |
CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
US20040110755A1 (en) | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
EP1751139B1 (en) | 2004-04-30 | 2011-07-27 | Bayer HealthCare LLC | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
ES2605792T3 (es) | 2004-05-13 | 2017-03-16 | Icos Corporation | Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana |
DK1778686T3 (da) | 2004-08-12 | 2009-01-12 | Pfizer | Triazolopyridinylsulfanylderivater som P38 MAP kinase-inhibitorer |
US20070078121A1 (en) | 2004-12-23 | 2007-04-05 | Flynn Daniel L | Enzyme modulators and treatments |
GB0500435D0 (en) | 2005-01-10 | 2005-02-16 | Novartis Ag | Organic compounds |
DE602006017694D1 (de) | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
DOP2006000233A (es) | 2005-10-28 | 2007-06-15 | Lilly Co Eli | Inhibidores de cinasa |
EA200870409A1 (ru) | 2006-04-04 | 2009-04-28 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Антагонисты киназы pi3 |
BRPI0717460A2 (pt) | 2006-10-20 | 2013-12-24 | Icos Corp | Composições de inibidores de chk1 |
DK2947072T3 (en) | 2008-03-17 | 2017-01-23 | Ambit Biosciences Corp | 1- (3- (6,7-DIMETHOXYQUINAZOLIN-4-YLOXY) PHENYL) -3- (5- (1,1,1-TRIFLUOR-2-METHYLPROPAN-2-YL) ISOXAZOL-3-YL) UREA AS RAF CHINESE MODULATOR IN TREATMENT OF CANCER DISEASES |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
WO2010038086A2 (en) | 2008-10-02 | 2010-04-08 | Respivert Limited | Novel compounds |
AU2009326148B2 (en) | 2008-12-11 | 2014-05-08 | Respivert Limited | p38 MAP kinase inhibitors |
RU2505539C2 (ru) | 2008-12-23 | 2014-01-27 | Эбботт Лэборетриз | Антивирусные соединения |
CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
US8809343B2 (en) | 2008-12-26 | 2014-08-19 | Fudan University | Pyrimidine derivative, preparation method and use thereof |
AR075974A1 (es) | 2009-03-27 | 2011-05-11 | Pathway Therapeutics Ltd | Pirimidinil y 1,3,5-triazinilbencimidazolsulfonamidas y su uso en terapia del cancer |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
GB0921731D0 (en) * | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
US8816069B2 (en) | 2010-03-15 | 2014-08-26 | Ube Industries, Ltd. | Method for producing amide compound |
GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
EP2556068B1 (en) | 2010-04-08 | 2019-01-23 | Respivert Limited | P38 map kinase inhibitors |
US9260410B2 (en) | 2010-04-08 | 2016-02-16 | Respivert Ltd. | P38 MAP kinase inhibitors |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
GB201010196D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
GB201010193D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
US8933228B2 (en) | 2010-06-17 | 2015-01-13 | Respivert, Ltd. | Respiratory formulations and compounds for use therein |
AU2012320300C1 (en) | 2011-10-03 | 2017-06-01 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP kinase inhibitors |
EP2578582A1 (en) * | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
EP2981526B1 (en) | 2013-04-02 | 2021-11-03 | Oxular Acquisitions Limited | Intermediates useful in the preparation of naphthylurea derivatives useful as kinase inhibitors |
US10284974B2 (en) | 2013-07-10 | 2019-05-07 | Starkey Laboratories, Inc. | Acoustically transparent barrier layer to seal audio transducers |
MX371353B (es) | 2014-02-14 | 2020-01-27 | Respivert Ltd | Compuestos heterociclicos aromaticos como compuestos antiinflamatorios. |
MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
-
2011
- 2011-10-03 EP EP11183688.8A patent/EP2578582A1/en not_active Ceased
-
2012
- 2012-10-03 US US14/349,356 patent/US9475796B2/en active Active
- 2012-10-03 JP JP2014532481A patent/JP6023204B2/ja active Active
- 2012-10-03 WO PCT/GB2012/052444 patent/WO2013050756A1/en active Application Filing
- 2012-10-03 EP EP12772382.3A patent/EP2763983B1/en active Active
-
2016
- 2016-09-08 US US15/259,505 patent/US9724347B2/en active Active
-
2017
- 2017-06-29 US US15/636,730 patent/US9993478B2/en active Active
-
2018
- 2018-03-19 US US15/925,384 patent/US10238658B2/en active Active
-
2019
- 2019-02-26 US US16/285,560 patent/US10813932B2/en active Active